Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHCNASDAQ:NGNENASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$23.32-0.2%$23.01$20.36▼$82.41$2.15B0.931.85 million shs1.98 million shsNGNENeurogene$19.50-2.9%$17.77$6.88▼$74.49$278.07M1.51251,207 shs221,809 shsTSHATaysha Gene Therapies$2.34-4.5%$2.50$1.05▼$3.31$502.30M0.972.92 million shs999,709 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare0.00%+9.13%+5.10%-9.54%-63.75%NGNENeurogene0.00%+24.04%-8.18%+155.03%-41.27%TSHATaysha Gene Therapies0.00%+0.84%-15.49%+93.55%+15.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHCAcadia Healthcare4.8124 of 5 stars4.33.00.05.02.00.02.5NGNENeurogene3.5928 of 5 stars4.43.00.00.01.81.71.3TSHATaysha Gene Therapies3.1524 of 5 stars4.51.00.00.02.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHCAcadia Healthcare 2.60Moderate Buy$47.94105.59% UpsideNGNENeurogene 2.75Moderate Buy$46.17136.75% UpsideTSHATaysha Gene Therapies 3.00Buy$8.20250.43% UpsideCurrent Analyst Ratings BreakdownLatest ACHC, NGNE, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.006/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.006/2/2025ACHCAcadia HealthcareStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $8.005/29/2025TSHATaysha Gene TherapiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/29/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.005/29/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.005/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHCAcadia Healthcare$3.15B0.68$4.92 per share4.74$33.09 per share0.70NGNENeurogene$930K299.00N/AN/A$20.89 per share0.93TSHATaysha Gene Therapies$8.33M60.30N/AN/A$0.35 per share6.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHCAcadia Healthcare$255.61M$2.0311.496.884.445.94%8.72%4.46%7/30/2025 (Estimated)NGNENeurogene-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)Latest ACHC, NGNE, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025ACHCAcadia Healthcare$0.70N/AN/AN/A$839.59 millionN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/12/2025Q1 2025ACHCAcadia Healthcare$0.35$0.40+$0.05$0.09$769.90 million$770.51 million5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHCAcadia HealthcareN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHCAcadia Healthcare0.721.351.35NGNENeurogeneN/A21.0321.03TSHATaysha Gene Therapies0.775.355.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHCAcadia HealthcareN/ANGNENeurogene52.37%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipACHCAcadia Healthcare2.00%NGNENeurogene9.92%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHCAcadia Healthcare25,50092.12 million90.28 millionOptionableNGNENeurogene9014.26 million12.85 millionOptionableTSHATaysha Gene Therapies180214.66 million206.55 millionOptionableACHC, NGNE, and TSHA HeadlinesRecent News About These CompaniesTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comBeyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies StockJuly 1, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCJuly 1, 2025 | marketbeat.comCantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical DataJune 29, 2025 | insidermonkey.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What HappenedJune 26, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's WhyJune 20, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from BrokeragesJune 19, 2025 | marketbeat.comEquities Analysts Offer Predictions for TSHA FY2025 EarningsJune 16, 2025 | marketbeat.comMillennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 12, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?June 11, 2025 | marketbeat.comCantor Fitzgerald Estimates TSHA FY2026 EarningsJune 11, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?June 10, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)June 10, 2025 | marketbeat.comTaysha Gene Therapies Grants Stock Options to New Employees Under Inducement PlanJune 8, 2025 | nasdaq.comWellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 7, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTaysha Gene Therapies Releases TSHA-102 Clinical Program UpdatesJune 4, 2025 | insidermonkey.comRetail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial DataJune 4, 2025 | msn.comPaul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) StockJune 4, 2025 | insidertrades.comTaysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific MeetingJune 3, 2025 | quiverquant.comQTaysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical ProgramJune 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHC, NGNE, and TSHA Company DescriptionsAcadia Healthcare NASDAQ:ACHC$23.32 -0.04 (-0.17%) Closing price 04:00 PM EasternExtended Trading$23.34 +0.02 (+0.09%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.Neurogene NASDAQ:NGNE$19.50 -0.59 (-2.94%) Closing price 04:00 PM EasternExtended Trading$19.60 +0.09 (+0.49%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Taysha Gene Therapies NASDAQ:TSHA$2.34 -0.11 (-4.49%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.03 (+1.28%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
